News
06-15-2015, 02:50 AM
Taiho Pharmaceutical Co., Ltd.(Japan) and Servier (France) announced on June 15 that they have entered into an exclusive license agreement on June 12, 2015 for the development and commercialization of TAS-102 (nonproprietary names: trifluridine and tipiracil hydrochloride) in Europe and other countries.
More... (http://www.news-medical.net/news/20150615/Taiho-Servier-sign-exclusive-license-agreement-to-develop-and-commercialize-TAS-102-drug.aspx)
More... (http://www.news-medical.net/news/20150615/Taiho-Servier-sign-exclusive-license-agreement-to-develop-and-commercialize-TAS-102-drug.aspx)